1 / 23

Surveillance of Drug Poisonings in Kentucky Using Multiple Data S ources

Surveillance of Drug Poisonings in Kentucky Using Multiple Data S ources. Terry Bunn, PhD Svetla S lavova, PhD Kentucky Injury Prevention and Research Center University of Kentucky Kentucky Department for Public Health August 14, 2012.

melia
Download Presentation

Surveillance of Drug Poisonings in Kentucky Using Multiple Data S ources

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Surveillance of Drug Poisonings in Kentucky Using Multiple Data Sources Terry Bunn, PhD Svetla Slavova, PhD Kentucky Injury Prevention and Research Center University of Kentucky Kentucky Department for Public Health August 14, 2012

  2. >50% of Kentucky adults surveyed reported being prescribed prescription pain relievers in last 5 years • 1 in 3 Kentuckians (32%) surveyed reported they knew someone close who abused prescription pain relievers compared to 1 in 5 Ohioans. • 40% of Kentuckians aged 14-29 knew someone close who abused prescription pain relievers compared to 14% of those 65+. Foundation for a Healthy Kentucky, Misuse of prescription pain relievers in Kentucky, Kentucky Health Issues Poll, December 2011

  3. Paulozzi et al. Vital signs: Overdoses of prescription opioid pain relievers- United States, 1999-2008. MMWR, 60(43) 1487-1492.

  4. Paulozzi et al. Vital signs: Overdoses of prescription opioid pain relievers- United States, 1999-2008. MMWR, 60(43) 1487-1492.

  5. Drug Overdose Identification Criteria • Inpatient hospitalization and emergency department data criteria: ICD-9 codes E850-858, E950.0-E950.5, E980.0-E980.5, and E962.0 or the principal diagnosis is 960 thru 979. • Drug overdose fatality data criteria: ICD-10 codes X40-X44, X60-X64, X85, and Y10-Y14.

  6. Age-Adjusted Drug Overdose Rates Among Kentucky Residents, 2000-2010

  7. Drugs Involved in Drug Overdose Deaths, 2002-2010

  8. Drug Overdose Deaths by Drug Category, 2002-2010

  9. Work-related Drug Overdose Deaths, 2000- 2010 (excluding 2007-2009)

  10. Kentucky Drug Overdose Hospitalizations by Age and Intent, 2000-2010.

  11. Kentucky Drug Overdose Hospitalizations by Gender and Intent, 2000-2010.

  12. Opiates and Benzodiazepine Overdose Hospitalizations of Kentucky Residents, 2000 - 2010 * *Data is based on primary and secondary diagnosis codes.

  13. Drug Overdose Hospitalizations by Billed Payer, 2000-2010 75 cases were billed to Workers’ Compensation

  14. Kentucky Drug Overdose ED Visits by Intent, 2008-2010* * 9% of cases not included due to missing information.

  15. Substances Present in Drug Overdose ED visits, 2008-2010

  16. Kentucky Drug Overdose ED Visits by BilledPayer, 2008-2010 20 cases were billed to workers’ compensation

  17. 2011 KASPER Reports Requested Kentucky Cabinet for Health and Family Services

  18. Top Prescription Drugs of Abuse (per dose) • Hydrocodone (Vicodin, Lortab, Lorcet) $6 - $8 • Oxycodone (Percocet, Percodan, Tylox) $6 - $8 • Methadone $10 - $40 • Diazepam (Valium) $1 - $2 • Fentanyl Patch $50, Lollipop (Actiq) $20 • Carisoprodol (Soma) $3 - $4 • Alprazolam (Xanax) $3 - $4 • Methylphenidate (Ritalin) $10 - $12 • Hydromorphone (Dilaudid) 4mg. $60 • Oxymorphone (Opana) 40mg. $44 (source:StreetRx) • $90 – Barbourville, KY • Charlie Chicon, “Prescription Medication Abuse”, National Association of Drug diversion Investigators Regional Training conference, June 2, 2011

  19. Acknowledgements This work was supported in part by Cooperative agreement numbers 5U6OH008483-08 from CDC-NIOSH and 5 U17/CE002017-02 from the CDC. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of CDC or NIOSH.

More Related